Pharmacological therapy for stable chronic obstructive pulmonary disease  

作　　者：Ruirui Duan Baicun Li Ting Yang 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,China-Japan Friendship Hospital,Beijing,China [2]National Center for Respiratory Medicine,Beijing,China [3]National Center for Respiratory Medicine Laboratories,Beijing,China [4]Institute of Respiratory Medicine,Chinese Academy of Medical Sciences,Beijing,China [5]National Clinical Research Center for Respiratory Diseases,Beijing,China

出　　处：《Chronic Diseases and Translational Medicine》2023年第2期82-89,共8页慢性疾病与转化医学（英文版）

基　　金：CAMS Innovation Fund for Medical Science,Grant/Award Number:2020-I2M-2-009;National Natural Science Foundation of China,Grant/Award Number:82270038;National Key Research and Development Program of China,Grant/Award Numbers:2022YFF0710800,2022YFF0710803。

摘　　要：In recent years,emphasis has shifted from preventing and treating chronic obstructive pulmonary disease(COPD)to early prevention,early treatment,and disease stabilization,with the main goal of improving patients’quality of life and reducing the frequency of acute exacerbations.This review summarizes pharmacological therapies for stable COPD.

关 键 词：BRONCHODILATOR chronic obstructive pulmonary disease inhaled corticosteroid pharmacological therapy 

分 类 号：R563.9[医药卫生—呼吸系统]